New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control
Ongoing
This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC